Amarin (NASDAQ:AMRN – Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect the company to post earnings of ($0.0972) per share and revenue of $43.76 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.
Amarin Stock Up 0.1%
Amarin stock opened at $12.11 on Tuesday. Amarin has a 52-week low of $11.25 and a 52-week high of $20.57. The firm has a market capitalization of $255.70 million, a price-to-earnings ratio of -12.29 and a beta of 0.76. The firm has a 50-day moving average price of $13.11 and a two-hundred day moving average price of $14.38.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the company. JPMorgan Chase & Co. began coverage on Amarin in a research note on Friday, August 21st. They set an “underweight” rating and a $13.00 target price on the stock. Zacks Research raised shares of Amarin from a “hold” rating to a “strong-buy” rating in a report on Monday, October 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Amarin in a research report on Thursday, October 15th. Finally, Wall Street Zen cut Amarin from a “buy” rating to a “hold” rating in a research report on Saturday, July 25th. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, Amarin has an average rating of “Hold” and a consensus price target of $13.00.
Read Our Latest Report on Amarin
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on developing and commercializing therapies intended to reduce cardiovascular risk. Its principal product is VASCEPA (icosapent ethyl), a prescription omega-3 fatty-acid medicine derived from highly purified eicosapentaenoic acid.
VASCEPA was initially approved in the United States to help lower triglyceride levels in certain patients and later received expanded approval to reduce the risk of cardiovascular events in eligible adults with elevated cardiovascular risk.
Featured Articles
- Five stocks we like better than Amarin
- AST SpaceMobile Faces Launch Risks as SpaceX Raises the Competitive Stakes
- GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
